Repare Therapeutics Inc. (NASDAQ:RPTX – Get Free Report) major shareholder Bvf Partners L. P/Il acquired 931,556 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $4,657,780.00. Following the completion of the acquisition, the insider now owns 5,155,739 shares in the company, valued at $25,778,695. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Repare Therapeutics Stock Performance
RPTX stock opened at $5.02 on Friday. Repare Therapeutics Inc. has a 1 year low of $3.08 and a 1 year high of $18.68. The firm has a market cap of $211.49 million, a P/E ratio of -2.17 and a beta of 0.09. The stock has a 50-day simple moving average of $7.15 and a 200-day simple moving average of $9.25.
Institutional Investors Weigh In On Repare Therapeutics
Large investors have recently modified their holdings of the stock. Barclays PLC acquired a new stake in shares of Repare Therapeutics in the second quarter valued at about $36,000. Deutsche Bank AG acquired a new stake in Repare Therapeutics during the 4th quarter valued at approximately $40,000. UBS Group AG grew its stake in Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after purchasing an additional 739 shares in the last quarter. Wells Fargo & Company MN grew its stake in Repare Therapeutics by 185.8% during the 4th quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after purchasing an additional 1,977 shares in the last quarter. Finally, SRS Capital Advisors Inc. acquired a new stake in Repare Therapeutics during the 1st quarter valued at approximately $49,000. Institutional investors and hedge funds own 85.09% of the company’s stock.
Analysts Set New Price Targets
About Repare Therapeutics
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
- Five stocks we like better than Repare Therapeutics
- Mega Cap Stocks: What They Are and How to Invest
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 11/13 – 11/17
- Investing in large cap stocks: Diving into big caps
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.